Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers-Reference-Cited by-同舟云学术

Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers

Published:2024-05-30 Issue:27 Volume:146 Page:18241-18252
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Huseman Eric D.¹^ORCID,Lo Anna¹^ORCID,Fedorova Olga²³,Elia James L.⁴^ORCID,Gueble Susan E.⁵,Lin Kingson¹⁴⁵^ORCID,Sundaram Ranjini K.⁵,Oh Joonseok¹⁶^ORCID,Liu Jinchan¹^ORCID,Menges Fabian¹⁷^ORCID,Rees Matthew G.⁸,Ronan Melissa M.⁸,Roth Jennifer A.⁸,Batista Victor S.¹^ORCID,Crawford Jason M.¹⁷⁹^ORCID,Pyle Anna M.¹²³^ORCID,Bindra Ranjit S.⁴⁵,Herzon Seth B.¹⁵¹⁰^ORCID

Affiliation:

1. Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States

2. Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520, United States

3. Howard Hughes Medical Institute, New Haven, Connecticut 06520, United States

4. Department of Pathology, Yale School of Medicine, New Haven, Connecticut 06520, United States

5. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut 06520, United States

6. Institute of Biomolecular Design & Discovery, Yale University, West Haven, Connecticut 06516, United States

7. Department of Chemistry, Chemical and Biophysical Instrumentation Center, Yale University, New Haven, Connecticut 06520, United States

8. Broad Institute of MIT and Harvard; Cambridge, Massachusetts 02142, United States

9. Department of Microbial Pathogenesis, Yale School of Medicine; New Haven, Connecticut 06520, United States

10. Department of Pharmacology, Yale School of Medicine; New Haven, Connecticut 06520, United States

Funder

National Cancer Institute

Yale Cancer Center

U.S. Department of Defense

National Institute of General Medical Sciences

Modifi Biosciences

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/jacs.3c06483

Reference93 articles.

1. DNA Damaging Drugs

2. Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window

3. DNA repair dysregulation from cancer driver to therapeutic target

4. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020

5. Glioblastoma and Other Primary Brain Malignancies in Adults